ReviewFrontiers in immunology2018
The Elusive Anti-
Review in Frontiers in immunology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
39 citing papers in PubMed, 72 citations in OpenAlex.
- Emerging antifungal strategies against Candida albicans using metal-organic frameworks and novel therapeutics: Opportunities and challenges.Journal of food and drug analysis · 2026Review
- A Novel Benzopyrone Derivative from Streptomyces chrestomyceticus ADP4 Inhibits Growth and Virulence Factors of Candida albicans.Current microbiology · 2025Article
- From High Protection to Lethal Effect: Diverse Outcomes of Immunization Against Invasive Candidiasis with DifferentInternational journal of molecular sciences · 2024Article
- Fungal vaccines and adjuvants: a tool to reveal the interaction between host and fungi.Archives of microbiology · 2024Review
- Immunogenicity and efficacy of CNA25 as a potential whole-cell vaccine against systemic candidiasis.EMBO molecular medicine · 2024Article
- Promising immunotherapeutic targets for treating candidiasis.Frontiers in cellular and infection microbiology · 2024Review
- Molecular cloning, expression, and purification, along withFrontiers in fungal biology · 2024Article
- Advancing Vaccine Strategies againstVaccines · 2023Review
- Construction ofVaccines · 2023Article
- Public Health Research Priorities for Fungal Diseases: A Multidisciplinary Approach to Save Lives.Journal of fungi (Basel, Switzerland) · 2023Review
- The interactions of Candida albicans with gut bacteria: a new strategy to prevent and treat invasive intestinal candidiasis.Gut pathogens · 2023Review
- Sources of Antifungal Drugs.Journal of fungi (Basel, Switzerland) · 2023Review
- Characterization of Defensin-like Protein 1 for Its Anti-Biofilm and Anti-Virulence Properties for the Development of Novel Antifungal Drug againstJournal of fungi (Basel, Switzerland) · 2022Article
- Pathogenesis and virulence ofVirulence · 2022Review
- Design of a multi-epitope vaccine against the pathogenic fungi Candida tropicalis using an in silico approach.Journal, genetic engineering & biotechnology · 2022Article
- Harnessing the Immune Response to Fungal Pathogens for Vaccine Development.Annual review of microbiology · 2022Review
- Evaluation of Anti-Journal of fungi (Basel, Switzerland) · 2022Article
- Immunosurveillance of Candida albicans commensalism by the adaptive immune system.Mucosal immunology · 2022Review
- Emerging Antifungal Targets and Strategies.International journal of molecular sciences · 2022Review
- Antibodies targetingFrontiers in immunology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Candidemia is a bloodstream fungal infection caused by
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.